CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that Sarepta, through Credit Suisse and Robert W. Baird & Co., intends to sell an amount of its common stock equal to approximately $37.5 million in gross proceeds in an underwritten offering, before deducting underwriting discounts and commission and other estimated offering expenses.

Credit Suisse and Robert W. Baird & Co. are acting as joint book-running managers of the proposed offering. The underwriters propose to offer the shares of common stock from time to time to purchasers directly or through agents, or through brokers in brokerage transactions on the Nasdaq Global Select Market, or to dealers in negotiated transactions or in a combination of such methods of sale, at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices.

Sarepta intends to use the net proceeds from the intended sale principally for product and commercial development, manufacturing, any business development activities and other general corporate purposes.

About Sarepta Therapeutics

Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of rare, infectious and other diseases.